Paragon 28, Inc. announced that on March 29, 2024, Steve Deitsch, Chief Financial Officer of the Company, notified the Company of his decision to resign from his position as CFO. Mr. Deitsch is pursuing an opportunity with OrganOx Limited. His resignation is not due to any disagreement with the Company on any matter, including related to the Company?s operations, policies, practices, financial reporting, or controls.

The Company has commenced a search for a permanent CFO. In connection with Mr. Deitsch?s resignation, the board of directors of the Company appointed Kristina Wright, a member of the Board since 2021 and current Chair of the Company?s Audit Committee and a member of the Nominating and Corporate Governance Committee, as interim CFO of the Company, effective April 3, 2024. During her time as interim CFO, Ms. Wright will remain on the Board, but will temporarily step down from her positions on the Audit Committee and Nominating and Corporate Governance Committee.

Ms. Wright served as the Chief Financial Officer of Cleerly, a digital healthcare company transforming the way clinicians approach the treatment of heart disease, from May 2023 to January 2024. Previously, Ms. Wright served as Vice President and General Manager of the Brain Modulation business of Medtronic, plc, a medical device company, from December 2021 to March 2023. Prior to that, she was Vice President and Chief Financial Officer for the Neuromodulation Operating Unit of Medtronic, plc, from July 2020 to November 2021 and has held various leadership positions at Medtronic, plc, in both finance and corporate development since August 2010.

Prior to Medtronic, plc, Ms. Wright worked at PricewaterhouseCoopers, LLP, in the Audit and Assurance and Transaction Services practices from 1999 to 2010. Ms. Wright holds a B.S. in Accounting from the University of Minnesota, and an M.B. A from the Fuqua School of Business at Duke University.